Humanin
Also known as: HN, MTRNR2, MT-RNR2, Rattin (rat homolog), HNG (S14G-humanin analog), [Gly14]-Humanin, Humanin G, HNG17, Colivelin (fusion derivative)
Mitochondria-derived peptide (MDP); 24-amino acid endogenous micropeptide encoded by a short open reading frame within the 16S ribosomal RNA gene (MT-RNR2) of m
What it is
Humanin is a small peptide the body makes naturally, mostly in brain and nerve cells. Researchers are studying it as a possible protector of brain and heart cells, and as a biomarker for Alzheimer's, diabetes, and age-related decline. No FDA-approved use yet; the research is still at an early stage.
The scientific side
Humanin (HN) is a 24-amino acid endogenous peptide encoded by a short open reading frame within the mitochondrial 16S rRNA gene (MT-RNR2) (PMID 26667157, PMID 39950467). It was first identified in brain tissue of an Alzheimer's disease (AD) patient as a factor antagonizing neuronal cell death induced by AD-associated insults. HN exerts cytoprotective, anti-apoptotic, anti-oxidant, and anti-inflammatory effects through multiple intracellular and extracellular mechanisms. Extracellularly, HN binds to a heterotrimeric cell-surface receptor (htHNR) composed of CNTFRα, WSX-1, and gp130, activating the JAK2/STAT3 pro-survival signaling pathway (PMID 19997871, PMID 21335658, PMID 16958985). Intracellularly, HN interacts with pro-apoptotic proteins such as BAX and IGFBP-3, preventing activation of apoptotic cascades. HN inhibits BAX-driven mitochondrial oxidative stress. HN activates AMPK, leading to phosphorylation of ULK1 and Beclin1, promoting mitophagy and clearance of damaged mitochondria. HN also inhibits Z-DNA/ZBP1-mediated necroptosis, promotes resolution of inflammation via efferocytic macrophages, and upregulates autophagy pathways promoting cell survival under metabolic stress. HN reduces weight gain, visceral fat, and increases glucose-stimulated insulin release. HN binds amyloid beta (Aβ), blocking Aβ aggregation enhanced by acetylcholinesterase. Its potent analog S14G-humanin (HNG) is reported to be approximately 1000-fold more potent than native HN. HN levels decline with aging but may increase compensatorily in some disease states (PMID 40090538, PMID 36642986).
Class: Mitochondria-derived peptide (MDP); 24-amino acid endogenous micropeptide encoded by a short open reading frame within the 16S ribosomal RNA gene (MT-RNR2) of mitochondrial DNA
Administration & storage
- Administration
- Intraperitoneal injection — HNG in rodent studies (PMID: 37814907PMID: 38163419PMID: 38054825PMID: 40639309PMID: 39435863)Subretinal injection — FITC-labeled Aβ model in vivo (PMID: 42333946)Intratracheal instillation — LPS for ALI model (not HNG itself) (PMID: 38054825)
- Storage
- No storage conditions for humanin or its analogs are described in any of the reviewed abstracts.
- Cautions
- HN has been shown to act as a pro-tumoral factor in glioblastoma, activating the ITGAV-TGFβ signaling axis and worsening survival outcomes in an orthotopic mouse model — potential oncogenic risk warrants caution.,A curvilinear (U-shaped) association between circulating humanin levels and cardiovascular mortality/morbidity has been observed in hemodialysis patients, suggesting that both very low and very high humanin levels may be harmful (PMID: 39102184, PMID: 41849628).,Humanin variants form amyloid-like β-sheet fibrils; the implications of fibrillization for administered peptide are not fully characterized.,All dosing data in the reviewed literature is from preclinical (animal) models; no human pharmacokinetic or safety data from clinical trials of exogenously administered humanin or analogs are present in the reviewed abstracts.,Sterile technique is essential when preparing any injectable peptide to prevent contamination and infection.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Alzheimer's disease (neuroprotection, biomarker, therapeutic candidate) Mixed
- Review: HN exhibits multiple intracellular and extracellular anti-cell death actions and antagonizes various AD-associated pathomechanisms including amyloid plaque accumulation. First identified in brain of AD patient as a 24-residue peptide antagonizing neuronal cell death. PMID 34626746 Niikura T. Biochimica et biophysica acta. General subjects. 2022.
- Review: HN counters progression and neuropathology of AD through anti-apoptotic signaling, insulin signaling, mitochondrial function, and autophagic activity. Cognitive improvement linked to maintenance of synaptic integrity and neurotransmitter modulation. PMID 35104624 Thiankhaw K et al. Biochimica et biophysica acta. General subjects. 2022.
- Review: HN improves hippocampal acetylcholine and attenuates oxidative stress/neurotoxicity. Aging reduces brain HN expression. Conflicting reports on whether circulating HN increases or decreases in AD patients. PMID 40090538 Alqahtani SM et al. European journal of pharmacology. 2025.
- Commentary: Humanin variant P3S (from mtDNA mutation m.C2639T, haplogroup N1b) may protect against APOE4-induced brain pathology. A mouse model showed HN P3S reduced APOE4-induced brain pathology. Higher proportion of Ashkenazi centenarian women carried APOE4 in N1b haplogroup, suggesting protective effect. PMID 38757793 Logan IS. Aging cell. 2024.
- HN protects neurons from AD-related neuronal death by binding to a novel IL-6-receptor-related receptor (CNTFRα, WSX-1, gp130) on cell surface. Effective against AD-related neuronal dysfunction in vivo in murine AD models. PMID 19997871 Matsuoka M, Hashimoto Y. Molecular neurobiology. 2010.
- RCT (ADEX): NDEV levels of humanin increased in the exercise group (especially APOE ε4 carriers) vs. controls. Findings suggest cognitive benefits of exercise may be mediated by upregulation of neuroprotective factors including humanin in neuron-derived extracellular vesicles. PMID 37730689 Delgado-Peraza F et al. Alzheimer's research & therapy. 2023.
- Cardiovascular disease (biomarker and cardioprotection) Mixed
- Human observational study (n=327): Circulating humanin lower in angina (124.22±63.02 pg/mL) and myocardial infarction (67.17±24.35 pg/mL) vs. controls (157.77±99.93 pg/mL). Lower circulating humanin was an independent risk factor for MI. Humanin levels predicted MACE in angina group. PMID 34525397 Cai H et al. Biochimica et biophysica acta. General subjects. 2022.
- Pilot prospective study (n=94 HD patients): Non-linear (U-shaped) relationship between humanin levels and composite CV/mortality outcome. Very low (<450.7 pg/mL) and very high (>759.5 pg/mL) humanin associated with highest hazard ratios (up to 5.84 unadjusted). PMID 39102184 Bolignano D et al. Journal of nephrology. 2024.
- Multicenter prospective study (n=83 HD patients): Humanin integration into established CV risk models significantly improved discrimination (ΔAUC 0.083–0.109), calibration, and reclassification. Both low (<462 pg/mL) and high (>778 pg/mL) humanin associated with increased CVMM risk. PMID 41849628 Bolignano D et al. Cardiorenal medicine. 2026.
- Review: MDP levels including humanin are diminished with aging and in CVD; humanin is a potential biomarker and therapeutic target in CVD. Discusses roles in apoptosis, inflammation, and oxidative stress in CVD onset and progression. PMID 38008175 Li Y et al. Journal of advanced research. 2024.
- Diabetes (type 1, type 2, gestational) and metabolic disorders Mixed
- Animal study: S14G-humanin administration in gestational diabetes mellitus mice reduced blood glucose, elevated serum insulin, improved lipid parameters, increased fetal survival, elevated antioxidant enzyme activity, reduced inflammatory cytokines and ER stress in placentas. PMID 35536048 Jiang H et al. Gynecological endocrinology. 2022.
- RCT (n=90 women with T2DM): Combined aerobic/resistance training (CT) + astaxanthin (AST) group showed significant increases in HN levels (p<0.05). CT and AST enhanced antioxidant defenses and reduced inflammation. CT+AST yielded best metabolic and anti-inflammatory effects. PMID 41249265 Basereh A et al. Scientific reports. 2025.
- Review: Humanin (encoded by MT-RNR2/16S rRNA gene) attenuates disease pathology including T1D, T2D, gestational diabetes, and other conditions. Discusses antidiabetic functions and evolutionary conservation of MDPs. PMID 38160808 Kal S et al. Peptides. 2024.
- RCT: Skeletal muscle HN protein levels increased by 35% after 12 weeks of resistance training in men with impaired glucose regulation (prediabetes). Significant correlation between serum HN and improvements in 2-hour glucose loading test in resistance training group. PMID 27923980 Gidlund EK et al. Physiological reports. 2016.
- Diabetic nephropathy (renal protection) Animal studies only
- Animal study (C57BL/6 and db/db mice) + in vitro: High-dose HNG reduced UACR by 49.5% in DN mice (from 103.91±7.68 to 52.50±4.02 µg/mg, P<0.001). HNG inhibited tubular necroptosis (52.2% reduction in p-MLKL), suppressed mitochondrial BAX translocation, reduced mitochondrial ROS, and blocked Z-DNA/ZBP1-mediated necropto PMID 42492881 Liu Y et al. European journal of pharmacology. 2026.
- Age-related macular degeneration (AMD) — retinal protection Mixed
- In vitro (ARPE-19) and in vivo (subretinal Aβ injection): HN activated AMPK, phosphorylated ULK1 and Beclin1, promoted Beclin1-Parkin interaction and mitochondrial translocation, facilitating clearance of Aβ-accumulated mitochondria. Preserved retinal function and RPE barrier integrity. PMID 42333946 Jang HY et al. Aging cell. 2026.
- Human observational + in vitro: Reduced humanin protein levels in AMD plasma vs. controls. HNG reduced inflammatory markers (CD62E, CD62P, ICAM-1, TNF-α, MIP-1α, IFN-γ, IL-1β, IL-13, IL-17A) in AMD RPE cybrid cells. PMID 35576057 Nashine S et al. Aging. 2022.
- Parkinson's disease (biomarker) Human observational
- Human observational (n=220; 154 PD, 66 controls): Increased humanin mRNA levels found in PBMCs of PD patients vs. controls. Suggested as possible marker for PD diagnosis; increase may reflect mitochondrial overexpression as cellular attempt to reduce apoptotic damage. PMID 36626066 Salemi M et al. Molecular biology reports. 2023.
- Polycystic ovary syndrome (PCOS) — biomarker and potential therapeutic Human observational
- Case-control (n=40 PCOS, n=40 controls): Serum humanin significantly lower in PCOS [474.9 (IQR 313.0–633.5) pg/mL] vs. controls [672.3 (481.7–764.6) pg/mL, p<0.001]. Negative correlations with testosterone, 2h insulin (OGTT), total cholesterol, LDL, and triglycerides. No difference in skeletal muscle humanin expression PMID 41186863 Sonmezoglu Kutuk I et al. Journal of endocrinological investigation. 2026.
- Premature ovarian insufficiency (POI) — protection Animal studies only
- Animal study (cyclophosphamide-induced POI in rats) + in vitro (COV434 cells): HNG mitigated ovarian damage, restored oestrous cycle and hormone concentrations, reduced follicular depletion and apoptosis. In vitro: HNG enhanced cell viability, reduced ROS/mtROS, increased Bcl-2 and p-STAT3, decreased Bax expression. PMID 40639309 Huang J et al. Reproductive biomedicine online. 2025.
- Animal study (D-galactose-induced POI in mice): 10 mg/kg HNG (i.p.) improved ovarian morphology, oestrous cycle (P=0.0036), increased follicle numbers, litters, oestrogen, and AMH. Increased antioxidant capacity, GSH; reduced MDA. Reduced granulosa cell apoptosis and senescence markers. Increased LC3 (autophagy). PMID 38163419 Huang J et al. Reproductive biomedicine online. 2024.
- Male infertility / oligoasthenozoospermia — protection Animal studies only
- Animal study (cyclophosphamide-induced oligoasthenozoospermia in mice): HNG treatment improved testis/sperm parameters, litter size, and serum testosterone. HNG activated Nrf2/GPX4 pathway, reduced ROS, MDA, Fe2+, and inhibited ferroptosis in testicular tissues and TM3/TM4 cells. PMID 39435863 Liu Y et al. Andrology. 2025.
- Review: HNG protects male germ cells against apoptosis induced by intratesticular hormonal deprivation, testicular hyperthermia, and chemotherapeutic agents. HN interacts with IGFBP-3 and BAX. HN participates in IL-12/IL-27 cytokine network for immune modulation. PMID 34534645 Lue Y et al. Biochimica et biophysica acta. General subjects. 2021.
- Intrauterine adhesions (IUA) — prevention and treatment Animal studies only
- Animal study (rat IUA model) + in vitro (Ishikawa cells): HNG (5 mg/kg/day i.p. for 21 days) attenuated endometrial fibrosis and IUAs, improved fertility (mating rate 80% vs. 40% in IUA group). HNG inhibited ferroptosis via Nrf2/GPX4 pathway in endometrial epithelial cells. PMID 37814907 Zou L et al. Human reproduction. 2023.
- Acute lung injury — protection Animal studies only
- Animal study (LPS-induced ALI in mice): HNG (3 and 6 mg/kg i.p.) alleviated alveolar wall thickening, neutrophil infiltration, apoptosis, inflammatory cytokines, ROS, MDA; increased SOD2. Mechanism: inhibition of NLRP3/caspase-1/GSDMD pyroptosis and TLR4/NF-κB signaling. PMID 38054825 Wu Y et al. Aging. 2023.
- Endothelial senescence (high glucose-induced) — protection In vitro only
- In vitro (HUVECs): HNG antagonized downregulation of SIRT6 in response to high glucose (15 mM), alleviated ROS production and cell senescence markers (p21, p53, p16, β-galactosidase). Suggests HN protects against vascular aging in diabetes via SIRT6. PMID 39730568 Li M et al. Scientific reports. 2024.
- Inflammation resolution — pro-resolving properties Mixed
- In vitro (human macrophages) + in vivo (mouse peritonitis): Humanin produced early by efferocytic macrophages during inflammation resolution. Preventive HUMANIN administration reduced leukocyte infiltration and pro-inflammatory cytokine secretion in peritonitis model. Humanin detected in gingival crevicular fluid of pe PMID 40877234 Maraux M et al. Cell death & disease. 2025.
- Glioblastoma — pro-tumoral role (safety signal) Mixed
- In vitro and in vivo (orthotopic glioblastoma mouse model): Humanin is upregulated in glioblastoma tumor tissue. Humanin activates ITGAV-TGFβ signaling axis, promoting migration, invasion, angiogenesis, and poor survival. Humanin-treated group showed worse survival vs. control. TGFBR1 inhibitor reduced this in vivo eff PMID 38942749 Ha CP et al. Cell death & disease. 2024.
- Adrenocortical carcinoma — impaired expression (biomarker) Human observational
- Human observational: Significant reduction in humanin mRNA expression in adrenocortical carcinoma (ACC) tissue vs. healthy controls. No significant change in serum humanin levels. Positive correlation between patient age and serum humanin; negative correlation between tumor size and LDL levels. PMID 38256114 Blatkiewicz M et al. International journal of molecular sciences. 2024.
- Cellular senescence — modulation of mitochondrial function In vitro only
- In vitro (primary human fibroblasts): Senescent cells showed elevated levels of humanin and MOTS-c. Humanin administration modestly increased mitochondrial respiration and selected SASP components in doxorubicin-induced senescent cells, partially via JAK pathway. PMID 29886458 Kim SJ et al. Aging. 2018.
- Insomnia (stress biomarker) Human observational
- Observational study (post-menopausal women with objective or paradoxical insomnia): HN levels were increased vs. control population in both insomnia groups, with no difference between the two types of insomnia. HN measured as a mitokine/stress response molecule. PMID 32420904 Martucci M et al. Aging. 2020.
Safety signals
- Pro-tumoral activity in glioblastoma: Humanin activates ITGAV-TGFβ signaling, enhancing glioblastoma cell migration, invasion, and angiogenesis; humanin-treated mice showed poor survival and aggressive tumor growth in orthotopic model PMID 38942749
- U-shaped (curvilinear) association with cardiovascular mortality in hemodialysis patients: both very low (<450.7 pg/mL) and very high (>759.5 pg/mL) circulating humanin levels associated with increased hazard of death or CV events PMID 39102184
- U-shaped association replicated in multicenter study: both low (<462 pg/mL) and high (>778 pg/mL) humanin linked to increased cardiovascular morbidity and mortality risk in HD patients PMID 41849628
- Amyloid-like fibrillization: humanin and variants form β-sheet fibrils detectable by transmission electron microscopy; fibrillization may affect membrane interaction and bioactivity. Implications of fibrillization on administration of HN discussed but not resolved PMID 40543583
- Conflicting reports on circulating humanin levels in Alzheimer's disease — some studies show increase (compensatory), others show decrease — precise role and safety implications of exogenous supplementation in AD remain unresolved PMID 40090538
- Excess mitokine (including humanin) concentrations associated with cancer and heart failure; dysregulation of mitokine levels can have deleterious consequences PMID 36642986
Contraindications
- Potential contraindication in glioblastoma or brain tumors: Humanin promotes glioblastoma progression via ITGAV-TGFβ axis and is associated with poor prognosis in glioblastoma patients PMID 38942749
Protocol
2 mg subcutaneous injection, 3x per week. Cycle: 8-12 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Not specified | High-dose HNG and low-dose HNG (exact mg/kg doses stated as 'high-dose' and 'low-dose' with high-dose significantly reducing UACR by 49.5%); specific mg/kg values not specified in abstract | Not specified | animal | Research PMID 42492881 |
| Intraperitoneal injection | 10 mg/kg HNG | 6 weeks | animal | Research PMID 38163419 |
| Intraperitoneal injection | HNG (dose described as 'different concentrations'; 10 mg/kg referenced as effective comparator dose based on abstract context for POI model) | Not explicitly stated (treatment following cyclophosphamide POI induction) | animal | Research PMID 40639309 |
| Intraperitoneal injection | 5 mg/kg/day HNG | 21 consecutive days | animal | Research PMID 37814907 |
| Intraperitoneal injection | 3 mg/kg and 6 mg/kg HNG | Single dose post-ALI induction | animal | Research PMID 38054825 |
| Oral (astaxanthin supplementation) | 8 mg/day astaxanthin (co-intervention; HN levels measured as outcome, not administered) | 8 weeks | human | Research PMID 41249265 |
| Intraperitoneal injection | 5 nmol of recombinant human CLSP (a humanin receptor agonist, not humanin itself) | Single dose | animal | Research PMID 45 |
| subcutaneous injection | 2 mg | 3x per week · 8-12 weeks | biohackers and longevity-focused adults | [Community] |
| subcutaneous injection | 2 mg | daily · 4-8 weeks | biohackers seeking accelerated neuroprotective or metabolic effects | [Community] |
| subcutaneous injection | 4 mg | 3x per week · 8-12 weeks | experienced biohackers / older adults (50+) focused on longevity | [Community] |
| subcutaneous injection | 1 mg | daily · 4-8 weeks | biohacker beginners or those running Humanin conservatively | [Community] |
| intranasal | 2 mg | daily · 4-8 weeks | biohackers prioritizing CNS / neuroprotective effects and avoiding injections | [Community] |
All studies (40)
- PMID 32420904 Human observational
Insomnia (stress biomarker) - PMID 36626066 Human observational
Parkinson's disease (biomarker) - PMID 38256114 Human observational
Adrenocortical carcinoma — impaired expression (biomarker) - PMID 41186863 Human observational
Polycystic ovary syndrome (PCOS) — biomarker and potential therapeutic - PMID 19997871 Mixed
Alzheimer's disease (neuroprotection, biomarker, therapeutic candidate) - PMID 27923980 Mixed
Diabetes (type 1, type 2, gestational) and metabolic disorders - PMID 34525397 Mixed
Cardiovascular disease (biomarker and cardioprotection) - PMID 34626746 Mixed
Alzheimer's disease (neuroprotection, biomarker, therapeutic candidate) - PMID 35104624 Mixed
Alzheimer's disease (neuroprotection, biomarker, therapeutic candidate) - PMID 35536048 Mixed
Diabetes (type 1, type 2, gestational) and metabolic disorders - PMID 35576057 Mixed
Age-related macular degeneration (AMD) — retinal protection - PMID 37730689 Mixed
Alzheimer's disease (neuroprotection, biomarker, therapeutic candidate) - PMID 38008175 Mixed
Cardiovascular disease (biomarker and cardioprotection) - PMID 38160808 Mixed
Diabetes (type 1, type 2, gestational) and metabolic disorders - PMID 38757793 Mixed
Alzheimer's disease (neuroprotection, biomarker, therapeutic candidate) - PMID 38942749 Mixed
Glioblastoma — pro-tumoral role (safety signal) - PMID 39102184 Mixed
Cardiovascular disease (biomarker and cardioprotection) - PMID 40090538 Mixed
Alzheimer's disease (neuroprotection, biomarker, therapeutic candidate) - PMID 40877234 Mixed
Inflammation resolution — pro-resolving properties - PMID 41249265 Mixed
Diabetes (type 1, type 2, gestational) and metabolic disorders - PMID 41849628 Mixed
Cardiovascular disease (biomarker and cardioprotection) - PMID 42333946 Mixed
Age-related macular degeneration (AMD) — retinal protection - PMID 45
5 nmol of recombinant human CLSP (a humanin receptor agonist, not humanin itself) Intraperitoneal injection (animal) - PMID 16958985
- PMID 21335658
- PMID 26667157
- PMID 28574175
- PMID 29886458 In vitro only
Cellular senescence — modulation of mitochondrial function - PMID 33145964
- PMID 34534645 Animal studies only
Male infertility / oligoasthenozoospermia — protection - PMID 36642986
Excess mitokine (including humanin) concentrations associated with cancer and heart failure; dysregulation of mitokine levels can have deleterious consequences - PMID 37814907 Animal studies only
Intrauterine adhesions (IUA) — prevention and treatment - PMID 38054825 Animal studies only
Acute lung injury — protection - PMID 38163419 Animal studies only
Premature ovarian insufficiency (POI) — protection - PMID 39435863 Animal studies only
Male infertility / oligoasthenozoospermia — protection - PMID 39730568 In vitro only
Endothelial senescence (high glucose-induced) — protection - PMID 39950467
- PMID 40543583
Amyloid-like fibrillization: humanin and variants form β-sheet fibrils detectable by transmission electron microscopy; fibrillization may affect membrane intera - PMID 40639309 Animal studies only
Premature ovarian insufficiency (POI) — protection - PMID 42492881 Animal studies only
Diabetic nephropathy (renal protection)